Evidence map›Paper›PMID 28506030›Full record

ArticleGut and liver2017

Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus.

Hideyuki Tamai, Yoshiyuki Ida, Akira Kawashima, Naoki Shingaki, Ryo Shimizu, Kosaku Moribata, Tetsushi Nasu, Takao Maekita, Mikitaka Iguchi, Jun Kato and 2 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut and liver, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Host-Directed Antiviral Therapy.Clinical microbiology reviews · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hideyuki TamaiSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Yoshiyuki IdaSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Akira KawashimaDepartment of Internal Medicine, Naga Municipal Hospital, Wakayama, Japan.
Naoki ShingakiSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Ryo ShimizuSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Kosaku MoribataSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Tetsushi NasuDepartment of Internal Medicine, Naga Municipal Hospital, Wakayama, Japan.
Takao MaekitaSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Mikitaka IguchiSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Jun KatoSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Taisei NakaoDepartment of Internal Medicine, Naga Municipal Hospital, Wakayama, Japan.
Masayuki KitanoSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThe present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic patients, and to elucidate the factors contributing to a sustained virologic response (SVR).

methodsOne hundred IFN ineligible patients infected with genotype 1b hepatitis C virus (HCV) were treated. Simeprevir (100 mg) was given orally together with reduced doses of PEG-IFN-α 2a (90 μg), and ribavirin (200 mg less than the recommended dose).

resultsThe patients' median age was 70 years, and 70 patients were cirrhotic. Three patients (3%) discontinued treatment due to adverse events. The SVR rate was 64%. Factors that significantly contributed to the SVR included the γ-glutamyl transferase and α-fetoprotein levels, interleukin- 28B (IL28B) polymorphism status, and the level and reduction of HCV RNA at weeks 2 and 4. The multivariate analysis showed that the IL28B polymorphism status was the only independent factor that predicted the SVR, with a positive predictive value of 77%.

conclusionsSimeprevir-based triple therapy with reduced doses of PEG-IFN and ribavirin was safe and effective for IFN ineligible patients infected with genotype 1b HCV. IL28B polymorphism status was a useful predictor of the SVR.

Indexed as

AgedAntiviral AgentsDrug Therapy, CombinationFemaleGenotypeHepacivirusHepatitis CHumansInterferon-alphaMalePolyethylene GlycolsProspective StudiesRecombinant ProteinsRibavirinSimeprevirSustained Virologic ResponseAntiviral AgentsInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRibavirinSimeprevirHepacivirusInterleukin-28BPegylated interferonRibavirinSimeprevir

Identifiers

PMID28506030
PMCPMC5491091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.